Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
Status:
Completed
Trial end date:
2019-07-06
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of AB023 (xisomab 3G3) in patients with end
stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two
cohorts. Within each cohort the patients will be randomized to receive either AB023 (xisomab
3G3) or placebo (at a ratio of 2:1 active: placebo).